Pharma Deals Review, Vol 2008, No 103 (2008)

Font Size:  Small  Medium  Large

Dynavax’s Deal Termination with Merck is followed by a New Agreement with GSK

Sally Mardikian PhD

Abstract


The US biotech, Dynavax, has become the latest company to enter into an option agreement with GlaxoSmithKline. This comes as a boost to the company following the termination of its agreement with Merck for its most advanced product – the Hepatitis B vaccine, Heplisav.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.